Global Macular Degeneration Testing And Therapeutics Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Macular Degeneration Type (Dry, Wet), And By Geography - Forecasts From 2022 To 2027

Global macular degeneration testing and therapeutics market is projected to grow at a CAGR of 3.39% during the forecast period to reach US$13.962 billion by 2027, from US$11.057 billion in 2020.

Age-related macular degeneration (AMD) is an eye disease that affects central vision. People with AMD cannot see people or objects directly in front of them. This common age-related eye condition affects people over the age of 50. It is the primary cause of unrepairable vision loss in people above 65 in industrialized countries. According to Dtsch Arztebl Int, in 2020, 200 million people were affected by AMD worldwide. The disease is responsible for approximately 9% of all cases of blindness. According to the national eye institute, the estimated number of people with AMD will double by 2050, from 2.07 million to 5.44 million. The majority of cases will continue to be dominated by white Americans. Hispanics, on the other hand, will see the fastest rate of increase, with a nearly six-fold increase in the number of expected cases from 2010 to 2050.

Global macular degeneration is expected to rise at a subsequent rate during the forecasted period as the rise in the ageing population across the globe, a growing number of surgical procedures and increased investment in R&D are all contributing factors to the expansion of the market. The growing population with eye disorders and hypertension will also drive industry growth. With COVID- 19 easing down, the ageing population will create demand for hospitals in terms of surgeries. Smoking, race, age, family history, and obesity are some reasons that cause AMD. The two forms of macular degeneration are wet and dry AMD. Dry AMD is non-treatable & Wet AMD can be treated with medications.

Key Developments

The food and drug administration (FDA) regulated a new drug to treat wet AMD & diabetic macular edema, the two leading causes of vision loss. It is the first injectable eye medication to be approved to treat both conditions, and it has a more flexible dosing regimen than current medications. Vabysmo is a significant step forward for ophthalmology. It is the first bispecific antibody approved for the eye and represents a significant advancement in treating retinal conditions such as wet AMD and diabetic macular edema. According to the American Academy of ophthalmology, anti-VEGF is breaking grounds in treating wet AMD.

By macular degeneration type, the global macular degeneration testing and therapeutics market can be segmented into dry and wet AMD. Dry AMD is most commonly found in humans. According to the American Academy of ophthalmology, 8 out of 10 people suffering from AMD have the dry form. It happens when a part of the macula gets thinner with age, and tiny clumps of protein grow, known as drusen, whereas wet AMD is less common but more serious. It happens when new and abnormal blood vessels grow under the retina. Wet AMD is curable, and investment in this segment is expected in the forecasted period.

By geography, the global macular degeneration testing and therapeutics market can be segmented into the Asia Pacific, North America, Middle East and Africa, South America, and Europe. North America is expected to hold a significant market share, followed by the Asia Pacific, which is expected to proliferate due to increased awareness of self-care and self-management during the forecast period.

COVID-19 Insights

The COVID-19 pandemic impacted the hospitals & clinics as due to a surge in cases, the footfall declined as people refrained from visiting the hospitals to eliminate the risk of infection. People who were injected with anti-VEGF & other medications and were left untreated due to the outbreak of COVID-19 were the most hit.

Global Macular Degeneration Testing and Therapeutics Market Scope:

Key Market Segments

• By Macular Degeneration type
  • Dry
  • Wet
• By Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • The Middle East and Africa
    • Saudi Arabia
    • Israel
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Indonesia
    • Thailand
    • Taiwan
    • Others

Frequently Asked Questions (FAQs)

Q1. What is the size of the global macular degeneration testing and therapeutics market?
A1. Macular Degeneration Testing And Therapeutics Market was valued at US$11.057 billion in 2020.

Q2. What will be the macular degeneration testing and therapeutics market size by 2027?
A2. The global macular degeneration testing and therapeutics market are projected to reach a market size of US$13.962 billion by 2027.

Q3. What are the growth prospects for the macular degeneration testing and therapeutics market?
A3. The macular degeneration testing and therapeutics market are projected to grow at a CAGR of 3.39% over the forecast period.

Q4. Which region holds the maximum market share in the macular degeneration testing and therapeutics market?
A4. North America is expected to hold a significant share in the macular degeneration testing and therapeutics market.

Q5. What factors are anticipated to drive the macular degeneration testing and therapeutics market growth?
A5. The macular degeneration testing and therapeutics market are expected to rise at a subsequent rate as the rise in the ageing population across the globe, a growing number of surgical procedures and increased investment in R&D are all contributing factors to the expansion of the market.